The double shared epitope: Its impact on clinical features and ultrasound findings in rheumatoid arthritis.
grayscale
power doppler
rheumatoid arthritis
shared epitope
ultrasound
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
13
12
2023
received:
07
09
2023
accepted:
21
12
2023
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
30
1
2024
Statut:
ppublish
Résumé
The link between the HLA-DRB1 locus and the risk of rheumatoid arthritis (RA) shown in genome-wide association studies strengthens the shared epitope (SE) hypothesis. We aimed to assess the impact of the double dose of the SE (double SE) on RA and explore its clinical associations, including the response to abatacept. We evaluated RA patients treated with csDMARDs or abatacept for HLA-DRB1 typing, clinical characteristics at baseline, and disease activity and ultrasound findings over 12 months. Patients with the double SE (n = 12) had significantly higher anti-citrullinated protein antibody (ACPA) titers, higher total grayscale (GS) score, and power Doppler (PD) score at baseline than patients without the double SE. Patients with the double SE exhibited reduced rates of SDAI remission and pronounced improvements in multiple disease activity between baseline and 12 months, including SDAI, CDAI, total GS score, and total PD score. When focusing on abatacept-treated patients, the decreases in SDAI, CDAI, and total PD score between baseline and 12 months were significantly larger in patients with the double SE. Patients with the double SE exhibited distinct characteristics, increased disease activity, and improved response to abatacept treatment.
Identifiants
pubmed: 38287542
doi: 10.1111/1756-185X.15030
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15030Subventions
Organisme : Ono Pharmaceutical
Organisme : Bristol-Myers Squibb
Informations de copyright
© 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376-381.
Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205-1213.
Ting YT, Petersen J, Ramarathinam SH, et al. The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. J Biol Chem. 2018;293(9):3236-3251.
González A, Nicovani S, Massardo L, et al. Influence of the HLA-DR beta shared epitope on susceptibility to and clinical expression of rheumatoid arthritis in Chilean patients. Ann Rheum Dis. 1997;56(3):191-193.
Balandraud N, Picard C, Reviron D, et al. HLA-DRB1 genotypes and the risk of developing anti citrullinated protein antibody (ACPA) positive rheumatoid arthritis. PLoS One. 2013;8(5):e64108. doi:10.1371/journal.pone.0064108
Massardo L, Aguirre V, García ME, et al. Clinical expression of rheumatoid arthritis in Chilean patients. Semin Arthritis Rheum. 1995;25(3):203-213.
Terao C, Yano K, Ikari K, et al. Brief Report: Main contribution of DRB1*04:05 among the shared epitope alleles and involvement of DRB1 amino acid position 57 in association with joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2015;67(7):1744-1750.
Oryoji K, Yoshida K, Kashiwado Y, et al. Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis. Ann Rheum Dis. 2018;77:1234-1236.
Rigby W, Buckner JH, Louis Bridges SJ, et al. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. Arthritis Res Ther. 2021;23(1):245.
Nishino A, Kawashiri S-Y, Koga T, et al. Ultrasonographic efficacy of biologic and targeted synthetic disease-modifying antirheumatic drug therapy in rheumatoid arthritis from a multicenter rheumatoid arthritis ultrasound prospective cohort in Japan. Arthritis Care Res. 2018;70(12):1719-1726.
Terslev L, Brahe CH, Østergaard M, et al. Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission. Arthritis Res Ther. 2021;23(1):1-8.
Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2958-2967.
Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54(12):3761-3773.